Modified Lee Symptom Scale (7-day severity)

Description:

A 30 item scale to capture the symptom burden of chronic graft-versus-host disease (cGVHD). Modifications include: 7-day recall period, response options changed from bother to severity.

cGVHD adversely affects patient quality of life, functional status, and survival after allogenic hematopoietic cell transplantation. A modification of the Original Lee Symptom Scale was used in the REACH3 trial, where the term “bother” is replaced with “severity” and the response options include ‘Did not have this problem, Mild, Moderate, Severe, Very severe’ to assess severity of the symptoms in the past week instead of a one-month recall period. To better match the original Lee Symptom Scale, this modified Lee Symptom Scale replaces “did not have this problem” with “no symptoms” and the recall period is “past 7 days” instead of “the past week”. Scoring of the MODIFIED LSS follows the same principles as the original scale. In some cases, two items are not included: “need to use oxygen” and “receiving nutrition from an intravenous line or feeding tube.” These two items may be removed from the scoring algorithm. Change scores are interpretable if the same formula is used for scoring enrollment and follow-up surveys. Contact the developer for code to score the instrument.

<ul>
   <li>May be used to assess the symptom burden of cGVHD in observational and interventional clinical trials</li>

</ul>

<ul>
<li>The original Lee Symptom Scale has been recommended for use by the NIH Consensus Development Project on Clinical Trials for cGVHD, though many trial sponsors have used this scale with a 7-day recall period in clinical trials prompting development of the modified LSS (7-day severity)</li>
<li>The symptom scale correlated highly with patients' self-assessed mild, moderate, and severe cGVHD manifestations in different analyses</li>
</ul>

cGVHD is the most common long-term complication of HCT and is associated with a decreased quality of life, impaired functional status, continued need for immunosuppressive medications, and increased non-relapse mortality. 20 – 50% of allogeneic transplant survivors develop cGVHD.

<ul>
<li>Stephanie Lee MD, MPH. Professor and Associate Director Clinical Research Division; David and Patricia Giuliani/Oliver Press Endowed Chair in Cancer Research</li>
</ul>

Copyrighted

English for United States of America

23-212_Stephanie Lee_mLSS_7 day Severity_mod. REACH_NCS_FHCC.pdf

mLSS-7-day-severity-23-212